http://www.xconomy.com/san-diego/2008/11/04/amylin-shareholder-floats-idea-of-selling-company/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 03:54:18 +0000 hourly 1 http://wordpress.org/?v=3.0.4 http://www.xconomy.com/san-diego/2008/11/04/amylin-shareholder-floats-idea-of-selling-company/comment-page-1/#comment-37217 it-shoppingmall.com » Diabetes the Looming Economic Disaster - Part IV Tue, 04 Nov 2008 17:58:54 +0000 http://www.xconomy.com/?p=6009#comment-37217 [...] Amylin Shareholder Floats Idea of Selling Company Biotech, diabetes, Byetta Luke Timmerman wrote: Activist shareholders are circling Amylin Pharmaceuticals. Eastbourne Capital, which owns a 12.5 percent stake in the San Diego-based biotech company, said on Monday that it is looking at ways to boost the stock price, including possibly selling the company, according to this Reuters report. Much has been made about declining demand for exenatide (Byetta), the company s top product for diabetes. Amylin (NASDAQ: AMLN) has seen its stock price plu [...] [...] Amylin Shareholder Floats Idea of Selling Company Biotech, diabetes, Byetta Luke Timmerman wrote: Activist shareholders are circling Amylin Pharmaceuticals. Eastbourne Capital, which owns a 12.5 percent stake in the San Diego-based biotech company, said on Monday that it is looking at ways to boost the stock price, including possibly selling the company, according to this Reuters report. Much has been made about declining demand for exenatide (Byetta), the company s top product for diabetes. Amylin (NASDAQ: AMLN) has seen its stock price plu [...]

]]>